Skip to Main Content
An official website of the United States government
Scheduled Maintenance: CDAS will be undergoing maintenance on Saturday, January 3rd from 7:30 AM to 9:30 AM U.S. Eastern Standard Time for updates to the website. During this time you may experience intermittent downtime.

Serum metabolomic profiling of prostate cancer risk in black men

Principal Investigator

Name
Demetrius Albanes

Degrees
M.D.

Institution
National Cancer Institute

Position Title
Senior Investigator

Email
daa@nih.gov

About this CDAS Project

Study
PLCO (Learn more about this study)

Project ID
2016-0014

Initial CDAS Request Approval
Jul 6, 2016

Title
Serum metabolomic profiling of prostate cancer risk in black men

Summary
Metabolomics is a robust bioanalytic method that involves the measurement and analysis of small molecular weight biochemicals from blood and other tissues. The product is a comprehensive library of metabolites that can help identify novel pathways which influence the risk of disease, with the potential of becoming targets for future therapeutic interventions. We have used metabolomics to identify potential risk for the development of diseases, including breast, colon, and prostate cancers. In a recent analysis of prostate cancer risk among men of European ancestry within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, measured metabolites were shown to be differentially associated with the risk of overall, aggressive, and non-aggressive prostate cancer. This study represented an agnostic approach, and discovered several lipid and energy metabolites associated with aggressive prostate cancer. Whether these metabolite associations also contribute to prostate cancer risk in black men is of interest given the well-documented higher rate of aggressive disease and mortality in black men relative to white men. An investigation into the metabolomic profile of black men may provide a biochemical basis for some of the black-white differences in trends and associations of prostate cancer risk.
We propose to build on a prior nested case-control study of black men within PLCO (EEMS 2014-00020), using pre-diagnostic serum samples (150 ul each) from existing and new incident prostate cancer cases in black men and their 1:1 matched controls. Serum samples will be measured by Metabolon Inc., using a non-targeted approach to detect and identify biochemical metabolites in circulation. Metabolon utilizes an ultrahigh performance liquid chromatography/mass spectroscopy (UHPLC/MS) and gas chromatography/mass spectroscopy (GC/MS) platform. This study has the potential to provide a more thorough and detailed understanding of prostate cancer risk in black men by allowing us to identify groups of metabolites that may be connected with known and novel risk factors and biological pathways related to risk in this population. Such an analysis has not previously been conducted in black men, and we have the potential to contribute to the field and help promote the development of new questions and research directions.

Aims

Our primary aim is to identify metabolites associated with prostate cancer risk in black men. A secondary aim is to determine which of the metabolites, if any, are candidates for future early detection or targeted therapeutic interventions.

Collaborators

Shakira Nelson (National Cancer Institute)
Tracy Layne (National Cancer Institute)
Stephanie J Weinstein (National Cancer Institute)
Jiaqu Huang (National Cancer Institute)
Alison Mondul (University of Michigan)
Steve Moore (National Cancer Institute)
Demetrius Albanes (National Cancer Institute)
Loic Le Marchand (University of Hawaii Cancer Center)
Lynne Wilkens (University of Hawaii Cancer Center)
Christopher Haiman (University of Southern California)

Related Publications